Gotrade News - Wall Street screens this week highlight two themes: cheap NASDAQ names with hedge fund support and high-growth revenue compounders. Analysts flag value picks alongside double-digit upside in growth leaders.
The lists reflect a market searching for quality at reasonable prices. Investors are balancing defensive value plays against secular growth stories trading well off recent highs.
Key Takeaways
- JD.com and Kimberly-Clark lead cheap NASDAQ picks ranked by hedge fund ownership.
- Snowflake and Booking Holdings top revenue growth screens with 37%+ analyst upside.
- Alnylam Pharmaceuticals enters the growth list after a Citi Buy initiation.
Cheap NASDAQ Names Drawing Hedge Fund Interest
According to Insider Monkey, the screen filters stocks trading below a forward P/E of 15. The list is ranked by Q4 2025 hedge fund ownership and refreshed May 22, 2026.
JD.com (JD) is held by 51 hedge funds and posted Q1 2026 net revenues of RMB315.7 billion. That figure represented 4.9% year-over-year growth, with operating margin reaching 5.6%.
The Chinese e-commerce group also returned capital through a $631 million share repurchase. That buyback retired roughly 1.6% of outstanding shares during the quarter.
Kimberly-Clark (KMB) appears with 56 hedge fund backers. Q1 2026 net sales reached $4.2 billion, a 2.7% year-over-year gain with organic sales up 2.5%.
Adjusted operating profit climbed to $732 million, up 3.7% on the prior year. Other names highlighted include Roper Technologies, Regeneron, Intuit, Gilead, Fiserv, Amgen, and T-Mobile US.
Revenue Growth Leaders With Analyst Upside
As reported by Insider Monkey, a separate screen targets stocks with 5-year revenue CAGRs above 25%. Names are ranked by analyst upside as of May 21, 2026.
Snowflake (SNOW) leads with a 51.23% five-year revenue CAGR and 37.73% analyst upside. The cloud data platform is currently held by 90 hedge funds.
TD Cowen reiterated a Buy rating with a $255 price target on Snowflake. The firm cited strong quarterly performance, cloud data warehouse consumption, and accelerating AI adoption.
Booking Holdings posts a 37.42% revenue CAGR and 37.78% analyst upside. The travel platform draws backing from 109 hedge funds, the highest in the growth cohort.
DA Davidson and TD Cowen trimmed Booking targets to $230 while keeping Buy ratings. Both flagged Middle East conflict risk as a near-term overhang on travel demand.
Per Insider Monkey, Alnylam Pharmaceuticals ranks fifth with a 49.66% revenue CAGR. The biotech offers 45.25% analyst upside and counts 67 hedge fund holders.
Citi initiated coverage with a Buy rating and a $380 price target on May 19. The firm called the year-to-date pullback an attractive long-term entry point.
HELIOS-B Phase 3 results for vutrisiran in ATTR-CM patients landed on May 12. The data support vutrisiran as a first-line treatment option in that indication.
